Last reviewed · How we verify
Mebeverine+Simethicone
Mebeverine relaxes smooth muscle in the gastrointestinal tract while simethicone reduces gas bloating by breaking down gas bubbles.
Mebeverine relaxes smooth muscle in the gastrointestinal tract while simethicone reduces gas bloating by breaking down gas bubbles. Used for Irritable bowel syndrome with abdominal pain, cramping, and bloating.
At a glance
| Generic name | Mebeverine+Simethicone |
|---|---|
| Sponsor | Abbott |
| Drug class | Antispasmodic + antifoaming agent combination |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Mebeverine is an antispasmodic agent that acts as a musculotropic relaxant on intestinal smooth muscle, reducing spasms and cramping without affecting normal peristalsis. Simethicone is a defoaming agent that reduces surface tension of gas bubbles in the gastrointestinal tract, allowing them to coalesce and be expelled more easily. Together, they address both the motor dysfunction and gas-related symptoms of irritable bowel syndrome.
Approved indications
- Irritable bowel syndrome with abdominal pain, cramping, and bloating
Common side effects
- Headache
- Dizziness
- Nausea
- Abdominal discomfort
Key clinical trials
- Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders (PHASE3)
- The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension (PHASE2, PHASE3)
- The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis (PHASE2, PHASE3)
- Probiotics as Adjuvant Therapy in the Management of Irritable Bowel Syndrome (NA)
- The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) (NA)
- Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico (PHASE4)
- Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS) (PHASE4)
- Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mebeverine+Simethicone CI brief — competitive landscape report
- Mebeverine+Simethicone updates RSS · CI watch RSS
- Abbott portfolio CI